Abstract
Introduction
Ischemic coronary disease is a leading cause of morbidity and mortality in the western world. Direct revascularization techniques, i.e. angioplasty or bypass surgery, aim to restore blood supply to the myocardium. In this context they could be associated with, or replaced in critical situations by, therapeutic agents designed to induce the outgrowth of new collateral vessels. During the past decade the cloning of the genes coding for angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor led to obtaining recombinant proteins, which enabled to validate their potential use as therapeutic agents w x 1-5 . VEGF is 38-to 46-kDa heparin-binding homod- imeric glycoprotein, acting as an endothelial cell-mitogen w x in vivo and vitro 6 . VEGF exerts its effects on endothelial cells through the activation of two cognate tyrosine w x kinase receptors, flt-1 and flk- 1 7,8 . Diverse strategies have been tested in peripheral vascular diseases. For instance intramuscular injections of basic fibroblast growth Ž . w x factor bFGF 1 , intravascular injections of vascular en-Ž . dothelial growth factor VEGF , using either the protein w x w x 2-4 andror a plasmid DNA coding for VEGF 5 result in an increase of blood flow, angiographic score and vascular density. Such an armentarium has validated the concept of therapeutic angiogenesis and paved the way for w x VEGF-based therapeutic application 9 .
In acute ischemia VEGF plays an important role in the w x angiogenesis associated with myocardial infarction 10 . In ( )a model of chronic ischemia, injections of VEGF improved w x regional blood flow 11-13 making this growth factor of almost immediate clinical relevance. However in the latter experiment 50% of the animals succumbed to severe hypotension. Although VEGF can stimulate angiogenesis and vascular permeability in animal models, it is not yet known whether such biological actions are mediated by different VEGF receptor activations. The present study was designed to determine whether this effect was species specific or could be prevented by inhibitors of nitric oxide and whether angiogenesis and hypotension were mediated by the same VEGF-receptor.
Methods

Materials and in Õitro assays
Ž
. Human recombinant VEGF 165 aminoacid isoform w x was expressed in a baculovirus expression system 14 . Anti-VEGF antibodies were raised in rabbits by monthly injections of 10 mg of VEGF165 in lymph nodes as w x previously described 15 . IgG were purified using protein A sepharose chromatography and further injected in coisogenic rabbits. 4-7 Months later blood samples were collected and IgG were purified using protein A sepharose chromatography and used for in vivo experiments. The Ž . specificity of anti-idiotypic antibodies AIA for Flk1rKDR was assessed by radioreceptor-assay using COS cells expressing either Flt-1 or Flk-1rKDR as already w x described 16 . One IgG preparation was further purified using anti-VEGF IgG affinity chromatography, enabling the purification of flk-1 specific agonists that represent 2% of the total IgG, and were used for in vitro experiments. Proliferation assays were performed on fetal bovine aortic Ž . endothelial cells FBAE seeded at 5000 per 12 multiwell plates in DMEM supplemented with 5% newborn calf Ž serum, 2 mM glutamine and antibiotics. Modulators 50 . pM; 2 ngrml VEGF or 8 ngrml AIA were inoculated every other day and the cells trypsinized and counted after 4 days in a Coulter counter. Ž . Ž Heparin 140 IU per mg was from Sigma L'Isle . 
Animal studies
All experiments were conducted in conformity with the guiding principles in the care and use of laboratory animals published by the US National Institutes of Health Ž . NIH Publication No 8523, revised 1985 .
Rabbit corneal pocket assay
The angiogenic response to anti-idiotypic antibodies w x was investigated using the rabbit corneal pocket assay 17 . Ž Pictures of the corneas were taken after 8 days =2.5, . OPMI microscope, Zeiss and the surface of the neovessels was assessed in a single-blind manner by an independent Ž operator according to a 5 grades scale. grade 0: no neovessel, grade 1: less than 1 mm long neovessels sprouting from the limbus, grade 2: 1 mm long neovessels, grade 3: 1 to 2 mm long neovessels, grade 4: neovessels extend-. ing to the implant .
The results are expressed as the mean and the standard error corresponding to the scores of 8 implants.
Hemodynamic studies
Ž Normotensive male Wistar-Kyoto rats Mean Arterial Blood Pressure, MABPs 95.3 " 3.6 mmHg; 200-300 g;
. 8-12 week of age; IFFA-CREDO, L'Abresle, France Ž were anaesthetized with sodium thiopental Inactin; 50 . mgrkg intraperitoneally . The trachea was cannulated to facilitate respiration and body temperature was maintained at 378C by means of a rectal probe connected to a homeothermic blanket. The carotid artery was cannulated Ž and connected to a TA400 pressure transducer Gould . Electronics, Ballainvilliers, France for the measurement of MABP. During surgical preparation, a first jugular cannula was used to infuse 100 mlrmin of a Ringer-Lactate Ž solution containing 3% wrv gelatin Plasmion8, Roger . Bellon Laboratories to replace fluid loss. It was thereafter used to infuse 20 mlrmin of a mixture of Plasmion8 and Ž . isotonic dextrose 1-1 . A second jugular cannula was used to infuse 10 mlrmin of 0.9% NaCl and 75 mgrkgrmin of sodium pentobarbital. A third jugular cannula was inserted to allow direct intravenous bolus injec-Ž . tion of substances to be studied total volume of 200 ml . All animals were allowed a 45 minute stabilisation period after completion of the surgical procedure.
MABP expressed in mmHg is reported, unless otherwise stated, as mean and standard error corresponding to four observations.
Statistical analysis
Rabbit corneal pocket assay: The Mann-Whitney test was used for comparison between different treatments. A p-value of less than 0.05 was considered significant. Hemodynamic studies: The Wilcoxon test was used for comparisons of data before and after the bolus injections of VEGF or other substances. The Mann-Whitney test was used for comparison between different treatments. A pvalue of less than 0.05 was considered significant.
Results
Anti-idiotypic agonists of Flk-1 r KDR induced cell proliferation and angiogenesis
We took advantage of the ant-idiotypic network to obtain VEGF internal images specific for the VEGF binding domains to each VEGF receptor. We found that 15-20% of the rabbits elicited anti-idiotypic antibodies which bound to flk-1 but not to flt-1. IgG purified from one blood Ž . 
Ž
. sample collected five months after the immunization AIA induced a mitogenic response on endothelial cells stronger than that obtained upon VEGF stimulation, whereas pre-Ž . Ž . immune IgG PI-Ab did not Fig. 1A . When similar amounts -on a molar basis-of VEGF or AIA were inserted in slow releasing implants in the coneal stroma Ž they were equally potent scores 2.90 and 2.72 respec-. tively in inducing sprouting of new capillaries from the limbus whereas PI-Ab remained inefficient. Angogenic scores obtained eight days after surgical insertion of the implants are reported in Fig. 1B. 
VEGF induced MABP decrease in a dose and time-dependent fashion
Intravenous bolus injection of VEGF caused a rapid, transient and dose-dependent decrease in Mean Arterial Ž . Blood Pressure MABP . The MABP fell within seconds of the injection, reached its minimum at 3 " 0.5 min and, in all instances, returned to baseline value within 20 min.
Ž . The vehicle control phosphate buffered saline did not affect blood pressure. The decrease in MABP was dose-de-Ž . Ž . pendent Fig. 2 . Injection of 0.5 mg, 3 mg n s 8 and 10 mg of VEGF resulted in a maximal decrease in MABP of 18.0 " 4.8 mmHg, 30.5 " 3.9 mmHg and 33.2 " 3.7 mmHg respectively. The ED for VEGF was found to be was evidenced when 200 mg of V-Ab were incubated with VEGF prior to injection, whereas the addition of 200 mg Ž . of PI-Ab failed to prevent the decrease in MABP Fig. 3 . However, none of these antibodies modified MABP when Ž . injected alone. Co-administration of heparin 1000 IU did not influence the pressure response to VEGF.
The VEGF injections were repeated after recovery of Ž . the MABP baseline value Fig. 4 . Compared to baseline MABP no significant decrease could be detected when a 20 minutes interval was allowed between injections, whereas a significant but lower decrease was observed Ž when the interval was extended to 40 minutes 16.5 " 3.6
. mmHg, p -0.05 .
AIA did not induce hypotension
Similar angiogenic scores were obtained in the rabbit corneal pocket assay, with 5 pmol of VEGF or AIA. We thus compared the haemodynamic effects of 60 nmol of VEGF to similar amounts of AIA. Ž AIA could not induce a decrease of MABP n s 8, not . shown . Furthermore when injected 10 minutes prior to the injection of 3 mg of VEGF they could not prevent a VEGF-induced MABP decrease similar to that observed in Ž . untreated animals Fig. 4 . 
An inhibitor of NO synthesis preÕented the VEGF induced MABP decrease
To see whether NO was involved in VEGF-induced hypotension, we investigated the effects of L-NMMA, an w x Ž inhibitor of NO synthesis 18 . L-NMMA was infused 25 . Ž mgrkgrmin for 30 minutes before VEGF injection 
Discussion
Our results indicate that VEGF activities on angiogenesis and arterial hypotension are mediated by distinct receptors.
Therapeutic angiogenesis has been evaluated as a means of restoring blood supply to the myocardium by providing new vessels for blood flow. VEGF is angiogenic in the w x chicken chorioallantoıd membrane 6 and in the rabbiẗ corneal pocket assays. It has been shown to increase the blood flow in coronaries when injected for four weeks in w x the vicinity of a gradual coronary occlusion 11 . Furthermore the angiogenic effect of intracoronary infusions of VEGF on collateral arteries to ischemic myocardium was w x confirmed in a canine model 12 . In a porcine model intra-coronary injections of VEGF was shown to improve Ž . blood flow, but to produce a significant reduction y40% in mean arterial pressure. 50% Of the VEGF-treated animals succumbed to hypotension following VEGF injection w x 13 . However, a recent report demonstrates that short-term w x treatment with VEGF, in contrast to FGF2 19,20 , failed to improve the collateral blood flow in a canine model.
With the aim of stimulating angiogenesis without inducing hypotension it would be important to know whether they are mediated by the same VEGF-receptor. We used a specific flk-1rKDR agonist prepared following the anti-idiotypic antibody strategy and demonstrated that it elicited neovessel sprouting in the rabbit corneal pocket assay and proliferation of bovine endothelial cell proliferation in vitro. AIA induced a stronger mitogenic response than VEGF, confirming our previous results on bovine brain w x capillary endothelial cells 16 and human stromal cells w x cultured from neonatal hemangiomas 21 . These results indicate that Flk-1rKDR homodimerization is sufficient to promote both phenomena. The observation that intravenous injections of AIA, in contrast to VEGF, failed to induce MABP decrease does not account for species-restriction since we previously demonstrated that it promoted w x also the proliferation of human cells 21 and tumoral w x angiogenesis in mouse 16 . Co-administration of heparin Ž . 1000 IU did not influence the pressure response to VEGF, in agreement with the absence of influence in angiogenesis of adding heparin to VEGF injections in a w x w x rabbit ischemic hindlimb model 2 . Yang et al. 22 re-Ž . ported that VEGF 1-250 mgrkg decreased MABP in w x rats and Hariawala et al. 13 reported that a dose of 500 mg induced a a40% decrease in mean arterial pressure in Ž .w x pigs of 25-30 kg of weight 17-20 mgrkg 12 . In our study such a decrease was achieved with 3-10 mg in rats Ž . of 300-400 g 10-30 mgrkg , a dose lower than that required in the models designed to detect endothelial cell Ž proliferation, namely the balloon injury model a50-250 w x. mgrkg, Ref. 23 and the femoral artery ligation model Ž w x. 250 mgrkg, 300-3000 mgrkg 24 . The hypotensive activity of VEGF appears to be similar among species and thus could be expected in man.
The observation that iterative injections of VEGF required a 40 minute delay to provide a significant effect implies that there is a haemodynamic adaptation to VEGF-induced hypotension that persists 40 minutes. On the other hand the VEGF receptors that mediate the blood pressure effect might be internalized after occupancy. This is supported by in vitro experiments from our laboratory where preincubation of VEGF with bovine aortic endothelial cells abolishes the availability of 90% of VEGF binding sites within 30 minutes. Removal of it enables a full reexpression of the receptors at the cell surface within 6 Ž . hours unpublished results . To investigate the hypothesis that heterodimerization of Flt-1 and Flk-1rKDR by VEGF was required for the MABP decrease we sought to occupy Flk-1rKDR receptors by injecting similar doses of AIA Ž and VEGF calculated from dose-response curves of their . mitogenic effects on endothelial cells . AIA had no effect and subsequent injection of VEGF induced a decrease in MABP similar to that observed in ''naive'' animals, thus indicating that heterodimerization of flt-1 and Flk-1rKDR receptors is not responsible for the VEGF-induced hypotension.
The vasodilatory activity of VEGF was not entirely unexpected. Indeed, in an isolated canine coronary artery w x Ku et al. 25 demonstrated a slow, dose dependent relaxw x ation, also observed by Lazarous et al. 19 . Such a vasodilatory effect could be prevented by mechanical disruption of the endothelium or by pretreatment with L-NMMA. In an attempt to implicate EDRFrNO in VEGF-induced hypotension Hariawala et al. injected L-NNA, a NO-synthase inhibitor, 6 minutes after injection of VEGF when w x the mean arterial pressure stabilized at its lowest level 13 . This resulted in a rapid restoration of mean arterial pressure. A definitive conclusion as to the implication of EDRFrNO could not be drawn from this experiment since we have shown that the decrease in MABP is spontaneously reversible and reaches its minimum within 3-4 minutes, a time interval comparable to the one reported by Hariawala et al. before the injection of L-NNA and the reversion of hypotension. To avoid such an artefact we pretreated the animals with L-NMMA, a competitive and w x labile inhibitor of NO-synthase 18 before the injection of VEGF. Such a treatment inhibited the hypotensive activity of VEGF. Furthermore 2 hours later, when L-NMMA was no longer efficient, a second injection of VEGF induced a significant decrease in MABP. Clearly our demonstration of reversible inhibition by L-NMMA of the VEGF-induced decrease in MABP confirms in vivo the EDRFrNO mediw x ation highlighted by others 22,25 . Taken together, our results show that the activation of Flk-1rKDR is sufficient to induce angiogenesis but is not involved in the potentially fatal VEGF-induced hypotension. This demonstration might have implications in coronary therapeutic angiogenesis and attention should be devoted to means of selectively activating Flk-1rKDR. Fortunately such selective ligands were recently obtained by 
